Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alk-Abello ASCHIX:ALKBC 85 EV-to-OCF is 22.16 as of Aug. 10, 2026, which is 40% below its 10-year median of 37.06. GuruFocus rates CHIX:ALKBC with a GF Score™ of 85/100 and a GF Value™ of kr207.82 (Modestly Overvalued). Among 1,405 Biotechnology companies, Alk-Abello AS ranks worse than 88.97% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Alk-Abello AS's Enterprise Value is kr48,500 Mil.
Alk-Abello AS's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was kr2,189 Mil. Therefore, Alk-Abello AS's EV-to-OCF for today is 22.16.
The historical rank and industry rank for Alk-Abello AS's EV-to-OCF or its related term are showing as below:
CHIX:ALKBc'
s EV-to-OCF Range Over the Past 10 Years
Min: -676.43 Med: 37.06 Max: 331.4
Current: 22.16
During the past 13 years, the highest EV-to-OCF of Alk-Abello AS was 331.40. The lowest was -676.43. And the median was 37.06.
CHIX:ALKBc's EV-to-OCF is ranked worse than 88.97% of 1405
companies
in the Biotechnology industry
Industry Median: -3.45
vs CHIX:ALKBc: 22.16
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alk-Abello AS's PE Ratio (TTM) for today is calculated as:
Alk-Abello AS's share price for today is kr256.30.
Alk-Abello AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr5.800.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Alk-Abello AS EV-to-OCF Related Terms
Alk-Abello AS EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Alk-Abello AS's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ALKBC vs VRTX, REGN, RVMD: EV-to-OCF Comparison
For the Biotechnology subindustry, Alk-Abello AS's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alk-Abello AS EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alk-Abello AS's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Alk-Abello AS's EV-to-OCF falls into.
Alk-Abello AS's current Enterprise Value is kr48,500 Mil.
Alk-Abello AS's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr2,189 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alk-Abello AS (CHIX:ALKBC) has a EV-to-OCF of 22.16 as of Aug. 10, 2026. This is 40% below median its historical median of 37.06. According to the industry distribution chart, Alk-Abello AS ranks #1250 out of 1405 companies in the Biotechnology industry, placing it in the top 89%.
Is Alk-Abello AS's EV-to-OCF too high?
Alk-Abello AS's current EV-to-OCF of 22.16 is 40% below median its 10-year median of 37.06. Based on the distribution chart, Alk-Abello AS ranks #1250 out of 1405 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alk-Abello AS has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alk-Abello AS's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alk-Abello AS ranks #1250 out of 1405 companies for EV-to-OCF. This places Alk-Abello AS in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Alk-Abello AS's current EV-to-OCF is 22.16, which is 40% below median its own 10-year median of 37.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alk-Abello AS stock overvalued right now?
Based on GuruFocus' analysis, Alk-Abello AS (CHIX:ALKBC) is currently considered Modestly Overvalued. The stock's GF Value™ is kr207.82, compared to a current price of kr256.30 — trading 23.3% above its estimated fair value. The current EV-to-OCF is 22.16, which is 40% below median its 10-year median of 37.06. Alk-Abello AS's overall GF Score™ is 85/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Alk-Abello AS (CHIX:ALKBC), the current EV-to-OCF is 22.16 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alk-Abello AS (CHIX:ALKBC) Overvalued in 2026?
Based on GuruFocus' analysis, Alk-Abello AS stock appears to be overvalued.
The current stock price of kr256.30 is trading 23.3% above its estimated GF Value™ of kr207.82.
GuruFocus considers Alk-Abello AS to be Modestly Overvalued.
Key valuation signals for CHIX:ALKBC:
EV-to-OCF: 22.16 (40% below median its 10-year median of 37.06)
GF Value™: kr207.82 vs. price of kr256.30 (23.3% above fair value)
No single metric tells the full story. See the CHIX:ALKBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
85GF Score
Get the complete analysis for CHIX:ALKBC
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ALKBC has been successfully added to your 
